Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Insulin resistance and beta-cell function--a clinical perspective

D R Matthews1

  • 1Oxford Centre for Diabetes, Endocrinology and Metabolism, Radcliffe Infirmary, Woodstock Road, Oxford OX2 6HE, UK. david.matthews@drl.ox.ac.uk

Diabetes, Obesity & Metabolism
|November 1, 2001
PubMed
Summary

No abstract available in PubMed .

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Plasma glucose in screening for diabetes and pre-diabetes: how much is too much? Analysis of fasting plasma glucose and oral glucose tolerance test in Sri Lankans.

BMC endocrine disorders·2019
Same author

Baseline characteristics in the VERIFY study: a randomized trial assessing the durability of glycaemic control with early vildagliptin-metformin combination in newly diagnosed Type 2 diabetes.

Diabetic medicine : a journal of the British Diabetic Association·2018
Same author

Development and validation of a Diabetes Risk Score for screening undiagnosed diabetes in Sri Lanka (SLDRISK).

BMC endocrine disorders·2016
Same author

Prediction of 10-year vascular risk in patients with diabetes: the AD-ON risk score.

Diabetes, obesity & metabolism·2015
Same author

Glycaemic efficacy of canagliflozin is largely independent of baseline β-cell function or insulin sensitivity.

Diabetic medicine : a journal of the British Diabetic Association·2015
Same author

Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes.

Diabetes, obesity & metabolism·2015